- Trial phase
- Preclinical (IND submitted/planned; Phase 1 initiation guided for Q3 2026)
- Time to market
- Unknown, years away. If Phase 1 begins on schedule (Q3 2026 guidance), first human safety data would likely come in 2027; any approval would be many years later, assuming the program survives early trials.
- Why 2/10
- The next hard, dated catalyst is Phase 1 initiation, which Sutro guided for Q3 2026 (per the August 12, 2026 earnings release), an operational milestone rather than a data binary, and on an asset that is one of several pipeline candidates behind lead program STRO-004, so the share-price impact within ~12 months is modest.
Watch for the company's confirmation that STRO-006 has entered Phase 1 (guided for Q3 2026), an operational milestone, not a data readout. The defining catalyst for Sutro's share price is STRO-004's expansion-cohort data (H1 2027 per the Q2 2026 release risk list), so treat STRO-006's near-term impact as modest pipeline news flow, not a binary.
Price Chart
Executive Summary
STRO-006 is Sutro Biopharma's preclinical, ITGB6 (integrin beta-6)-targeting antibody-drug conjugate (ADC). At AACR 2026 (April 19, 2026) it showed dose-dependent antitumor activity in non-small-cell lung cancer and head-and-neck cancer models, and the company guided that it is "on track for Phase 1 initiation in Q3 2026" in its August 12, 2026 earnings release. It is one of several next-generation ADC candidates (STRO-004, the Phase 1 tissue-factor lead, and STRO-227, a PTK7 dual-payload ADC) and carries no human data yet, so its value to STRO shareholders is real but distant, an option on the platform rather than a near-term binary.
How It Works
STRO-006 is an antibody-drug conjugate (ADC), a targeted cancer therapy built like a guided missile. One part is an antibody that homes in on ITGB6 (integrin beta-6), a protein found on the surface of certain tumors, and the other part carries a chemotherapy "payload." The antibody binds to cancer cells that express ITGB6, delivering the toxin directly to the tumor instead of flooding the whole body. Sutro's platform makes these molecules in engineered cells, which the company says allows precise control of where the drug attaches. Preclinical data presented at AACR 2026 showed dose-dependent tumor shrinkage in mouse models of non-small-cell lung cancer and head-and-neck cancer. No human data exist yet.
Trial Status
STRO-006 is in preclinical development. At AACR 2026 (April 19, 2026) Sutro presented dose-dependent antitumor activity in NSCLC and head-and-neck cancer models with an IND submission planned for 2026 (per that release). In its Q2 2026 earnings release (August 12, 2026), the company said STRO-006, described there as an "ITGB6-targeting ADC", was on track for Phase 1 initiation in Q3 2026. No clinical trial record for STRO-006 appeared in SecBot's ClinicalTrials.gov-ingested pipeline data, consistent with it not having started human dosing yet.
The Two-Sided Case
Upcoming Catalysts
- Confirmation of STRO-006 Phase 1 initiation (on track for Q3 2026 per the August 12, 2026 earnings release)
- IND submission for the STRO-227 PTK7 dual-payload ADC (targeted for 2026), which the company groups with STRO-006 as next-gen platform validation
- STRO-004 Phase 1 expansion-cohort data (H1 2027 per Q2 2026 filing risk notes), the pipeline event with the most share-price impact
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Sutro Biopharma, Inc. PRESS-RELEASE STRO ·Originating report